Chris Pappas

Tyler’s Law

This bill requires the Department of Health and Human Services (HHS) to complete, within one year after the bill’s enactment, a study on how frequently Medicare-participating hospital emergency departments test for fentanyl in patients experiencing an overdose, the costs associated with such testing, and how such testing may impact patients.

Within six months after the study’s completion and based on its results, HHS must issue guidance regarding (1) whether hospital emergency departments should implement fentanyl testing as a routine procedure for patients experiencing an overdose, (2) how to ensure clinicians know which substances they are testing for in routine drug tests, and (3) how fentanyl testing may affect the future risk of overdose and other health outcomes.

Ellie Helton, Lisa Colagrossi, Kristen Shafer Englert, Teresa Anne Lawrence, and Jennifer Sedney Focused Research Act or Ellie's Law

This bill authorizes through FY2030 appropriations for the National Institute of Neurological Disorders and Stroke to conduct or support research on unruptured brain aneurysms in a patient population diversified by age, sex, and race.

This resolution congratulates the people of Greece as they celebrate the 205th anniversary of the War of Greek Independence. The resolution also expresses support for the principles of democracy, human rights, and the rule of law to which the people of the United States and Greece are committed.

End Special Treatment for Congress at Airports Act of 2026

This bill prohibits the Transportation Security Administration (TSA) from providing a Member of Congress with expedited or preferential access to or through airport security screenings.

Specifically, TSA funds may not be used to

• exempt a Member of Congress from TSA passenger and baggage screening, or

• provide a Member of Congress with priority or expedited access to a screening location based on their position.

TSA must update its policies and procedures to ensure compliance with this bill.

Extending WIC for New Moms Act

This bill amends the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) to extend the eligibility periods for breastfeeding and postpartum women.

Specifically, a state program may elect to certify a breastfeeding woman for up to 24 months (currently 1 year) postpartum. The bill also expands the eligibility period for postpartum women to up to 24 months after termination of pregnancy (currently 6 months).

The Department of Agriculture must submit a report to Congress evaluating the effect of these changes to the program on (1) maternal and infant health outcomes, (2) breastfeeding rates, and (3) qualitative evaluations of family experiences under WIC.

This joint resolution redesignates the memorial to Robert. E. Lee in Arlington National Cemetery as the Arlington House National Historic Site.

This resolution condemns Iran's state-sponsored persecution of the Baha'i religious minority and Iran's continued violation of international human rights treaties. The resolution calls on Iran to (1) immediately release Baha'is and others imprisoned or detained solely on account of religion, (2) end its state-sponsored campaign of hate propaganda against the Baha'is, and (3) reverse certain policies that discriminate against Baha'is and other religious minorities. The resolution also urges the President and the Department of State to impose sanctions on Iranian officials and others who are responsible for serious human rights abuses, including abuses against Iran's Baha'i community.

Safe Air on Airplanes Act

This bill directs the Federal Aviation Administration (FAA) to update regulations to phase out and prohibit bleed air systems in certain types of aircraft. In general, a bleed air system uses compressed air that is taken from an aircraft engine that is upstream of the combustion chamber and provides pressurized air for the aircraft’s environmental control system (e.g., ventilation).

Under the bill, the FAA must

• prohibit new turbine and turboprop aircraft designs from using bleed air systems,

• require (beginning seven years after the bill’s enactment) that any bleed air system in a newly manufactured aircraft is fitted with a filter (i.e., a device that removes gaseous and particulate components of oil fumes), and

• provide for a phaseout (over a 30-year period) of the use of bleed air systems in existing turbine and turboprop aircraft designs.

Infant Formula Safety Modernization Act of 2026

This bill directs the Food and Drug Administration (FDA) to expand requirements for the testing of infant formula and formula manufacturing facilities for pathogens and microorganisms.

Current regulations generally require manufacturers to test finished formula products for Cronobacter and Salmonella. The FDA tests manufacturing facilities for these contaminants in regular inspections, but manufacturers are not required to test their own facilities.

Within 90 days of the bill's enactment, the FDA must issue a final rule requiring manufacturers to test their facilities and finished formula products for certain pathogens and microorganisms, including Clostridium botulinum (which causes botulism). These regulations must include a recommended frequency for facilities testing, including requirements for testing different areas based on their proximity to formula products.

Manufacturers must notify the FDA within one business day of any positive result for one of the specified pathogens or microorganisms in a finished formula product, even if the product is still in the manufacturer’s possession. (Currently, notice is required only if the affected product has left the manufacturer’s facilities.) Manufacturers must also retain records of any positive result (from a test of formula or facilities).

The FDA must notify Congress within one business day of

• receiving notice of a positive test result for a finished formula product, or

• recommending official corrective action to address the findings of a facility inspection.

Finally, the regulations must explicitly require the FDA to enforce consistent inspection and compliance standards for all formula products, including imported products.